-- Aaron Sato, Ph.D., Chief Scientific Officer of Twist Biopharma, to
Deliver Keynote Address –
-- User Group Meeting to Feature Scientists Discussing Applications of
Twist Libraries to Discover and Optimize High Quality Antibody Drugs --
SAN FRANCISCO--(BUSINESS WIRE)--Apr. 1, 2019--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
using its silicon platform, today announced five presentations at PEGS
(The Essential Protein Engineering Summit) taking place April 8-12, 2019
at the Seaport World Trade Center in Boston. The presentations include
an overview of Twist Biopharma as well as proof-of-concept data for its
GPCR library and antibody optimization solutions from Aaron Sato, Ph.D.,
Chief Scientific Officer of Twist Biopharma, and four poster
presentations.
The presentations will occur on Monday, April 8th. The
company will also host a User Group Meeting on Wednesday, April 10th
at 6:45 pm ET. Full event information can be found here.
The details for the presentations are as follows:
Presentation at PEGS
Date: Monday, April 8, 2019
Time: 1:50 pm - 2:20 pm
Location:
Auditorium
Speaker: Aaron Sato, Ph.D., CSO, Twist Biopharma
Talk
Title: Synthetic DNA Technologies Enable Antibody Discovery and
Optimization
Poster Presentations
Date: Monday, April 8, 2019
Time: 5:40 pm – 7:15 pm
Location:
Commonwealth Hall
Poster Session: A
Poster Number: A103
Precision Synthesis of Variant Libraries
Enables Comprehensive Interrogation of Single Site Variant Space
Poster Number: A104
A High-Throughput Platform to Develop
Highly Potent and Functional Antibodies Against G-Protein Coupled
Receptors
Poster Number: A105
Twist Bioscience's Silicon-Based DNA
Synthesis Platform Enables the Construction of Focused Variant Libraries
with Unprecedented Precision
Poster Number: A106
Rapid Optimization and Humanization of
an Anti-PD1 Antibody
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.
Follow us on Twitter
| Facebook
| LinkedIn
| YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005252/en/
Source: Twist Bioscience Corporation
Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com
Twist Media Contact:
Angela Bitting
925-202-6211
media@twistbioscience.com